Print

Executive Insights

Volume XVIII, Issue 2 | February 5, 2016 | By: Pierre Jacquet, David Barrow, Peter Rosenorn Operational scale-up before first product launch Engagement models in the U.S. and Europe for first product launch Customer-oriented operating model Tracking tools for enterprise readiness

In this Executive Insights, we address the key principles that biopharma executives should bear in mind when transitioning a biopharma organization from purely research and development to an established, fully integrated drug company. Learn about L.E.K.’s proprietary approach to enterprise readiness and how it can be used successfully in operational scale up.

Volume XVII, Issue 38 | December 29, 2015 | By: Jonathan Kfoury, Alex Vadas Comparison of Various Pathogen Detection Technologies Impact of Emerging Dx Techniques on Antibiotic Treatment Paradigm

Approximately 700,000 deaths annually are caused by antimicrobial-resistant microorganisms, and the Organization for Economic Co-operation and Development (OECD) predicts that current rates of antibiotic resistance will result in cumulative costs of roughly $3 trillion by 2050. In this Executive Insights, we outline several challenges that have limited the use of diagnostic testing to drive early-line treatment decisions for serious bacterial infections, as well as our recommendations for the path forward.

Volume XVII, Issue 28 | August 19, 2015 | By: Brian Baranick, Alex Vadas Key CDx Development and Commercialization Steps and Partner Types Approved Personalized Medicine Oncology Drugs as of 20141 Examples of Drivers of CDx-Related Patient Leakage Examples of How Reference Labs Can Support CDx Commercialization

With the move toward more personalized medicine plans outside of just oncology, biopharma companies are developing more companion diagnostic (CDx) tests to give patients access to new therapies. In this Executive Insights, L.E.K. addresses CDx test barriers to commercialization and recommends partnering with large reference laboratories to avoid overtaxing IVD companies.

Volume XVII, Issue 24 | July 27, 2015 | By: Brian Baranick, Alex Vadas Worldwide CDx-Informed Drug Revenue 2013 Late-Stage Clinical Trial Pipeline by Trial Type and Therapeutic Area Novel CDx Tools Partnerships on Novel CDx Technologies Examples of Novel Technology Partnerships

The last decade has seen a shift toward personalized medicine that leverages biomarkers and related companion diagnostics (CDx). In this Executive Insights, L.E.K. addresses the trends driving adoption of novel technologies for companion diagnostics. The freight train of personalized medicine is hurtling forward, and biopharma companies would be wise to thoroughly assess the opportunities for novel technologies before initiating adoption.

Volume XVII, Issue 15 | April 30, 2015 | By: Jonas Funk, Lucas Pain, Monish Rajpal Accelerating Hospital Trends Expected Change in Influence of Hospital Administration on MedTech Purchases Key Activities Aimed at Addressing Hospital Needs Hospitals Perceived Value of Potential MedTech Services

L.E.K. believes that the MedTech industry has hit an inflection point and that the continued industry shake-out will mirror the shake-out occurring among its customers (i.e., hospital systems). In the 2015 L.E.K. Strategic Hospital Priorities Study, many of the trends revealed in the 2014 study are again impacting hospital suppliers and are indeed accelerating — with vital implications for suppliers. 

Volume XVII, Issue 9 | March 5, 2015 | By: Arnaud Sergent, Serge Hovsepian, Ben Faircloth Value Chain of the Pharmaceutical Industry Outsourced Manufacturing Market Growth Drivers Specialization Strategies Pain Medicine APIs Classification Examples of Galenic Forms Product Life Cycle Support Opportunities

In this Executive Insights, L.E.K. Consulting's Arnaud Sergent, Serge Hovsepian and Ben Faircloth examine the opportunities and risks in the outsourced manufacturing market, and identify four specialization strategies that CMOs can adopt in order to build a differentiated and successful business in this buoyant but complex market.

Volume XVII, Issue 7 | March 3, 2015 | By: Sue St. Sure, Nurry Hong The Rise and Spread of Monoclonal Antibodies (mAbs) Benefits of Novel Therapies

Pharma and biotech executives need to think as much about drug delivery as they do about research and development, so L.E.K. Consulting has devised a three-step process of realization: Is a drug delivery strategy important to your organization? Will a one-off approach suffice or do you need a platform? Which technologies matter for the drugs in your pipeline? Those that can get drug delivery right in this evolving biologics landscape will capture crucial share in the marketplace.

2015 State of the Industry | March 1, 2015 | By: L.E.K. Consulting

Executives in the biopharma and life sciences industry face many critical strategic questions in 2015. Here, L.E.K. Consulting shares its views on the key challenges and opportunities for life sciences companies, as well as the solutions that senior executives are already turning to.

Volume XVI, Issue 46 | December 24, 2014 | By: Jonathan Kfoury Estimated cost per QALY

In this Executive Insights, L.E.K. Managing Director Jonathan Kfoury outlines the issues facing the significant economic constraint on antibiotic value capture across the U.S. and Europe, and discusses possible solutions to unleashing a new wave of antibiotic development and addressing the reimbursement barrier head-on. 

Volume XVI, Issue 40 | November 24, 2014 | By: Vassilis Economides, Manny Picciola, Simon Horan The Four Dimensions of Strategy Activation The Strategy Activation Roadmap

Typically, organizations have adopted a traditional two-stage approach which separates a strategy’s theory from the practice of its implementation. However, this approach is not appropriate for most modern organizations and increases the cost of strategic change, while reducing its chances of success. L.E.K. partners Vassilis Economides, Manny Picciola and Simon Horan explain why the traditional two-staged approach is no longer fit for purpose, and present an alternative solution: the "strategy activation" approach.

Pages